Curium Expands PYLCLARI® Rights to 56 Additional Countries, Bringing Precision Prostate Cancer Imaging Closer to Patients Worldwide

• Curium has expanded its supply of PYLCLARI® (18F-piflufolastat) to more patients with prostate cancer around the world

Boston, MA, 30^th September, 2026 – Curium™ has expanded its supply of PYLCLARI® (18F-piflufolastat) into 56 additional countries across Africa, the Middle East, Asia-Pacific, Latin America, and other international growth markets. The agreement significantly broadens Curium’s ability to bring advanced Prostate-Specific Membrane Antigen (PSMA) PET imaging to patients with prostate cancer around the world, subject to applicable local regulatory requirements.

Building on Curium’s existing licensing rights, the expansion reinforces the company’s commitment to improving access to innovative nuclear medicine solutions and addressing disparities in access to precision cancer diagnostics. Curium currently commercializes PYLCLARI® across Europe through one of the region’s broadest PET radiopharmaceutical supply networks.

Ciril Faia, CEO Curium International said, “Access to advanced prostate cancer imaging remains uneven across many parts of the world. This agreement gives Curium the opportunity to work with health authorities, health care professionals and local partners to expand access to PYLCLARI in additional markets. Our priority is to navigate the necessary registration and reimbursement pathways while building the reliable supply infrastructure needed to support patients and physicians.”

Curium will work closely with healthcare authorities, physicians and local partners to pursue registration, reimbursement and commercialization activities across the newly added territories, with the goal of making high-quality PSMA PET imaging available to more patients who can benefit from precision prostate cancer diagnostics.